{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:55:31Z","timestamp":1790769331128,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":30,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["92259104"],"award-info":[{"award-number":["92259104"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-77375-6","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T09:14:03Z","timestamp":1788167643000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical attribute-based risk matrix for prognostication in immunotherapy-treated non-small cell lung cancer"],"prefix":"10.1038","volume":"17","author":[{"given":"Lu","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hairui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bosinan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuju","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoshuo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taixue","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanchao","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuyang","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2639-6301","authenticated-orcid":false,"given":"Song","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9549-620X","authenticated-orcid":false,"given":"Li","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3355-9930","authenticated-orcid":false,"given":"Jiangdian","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"77375_CR1","doi-asserted-by":"publisher","first-page":"4592","DOI":"10.1158\/1078-0432.CCR-18-1538","volume":"25","author":"DB Doroshow","year":"2019","unstructured":"Doroshow, D. B. et al. Immunotherapy in Non-small Cell Lung Cancer: Facts And Hopes. Clin. Cancer Res. J. Am. Assoc. Cancer Res. 25, 4592\u20134602 (2019).","journal-title":"Clin. Cancer Res. J. Am. Assoc. Cancer Res."},{"key":"77375_CR2","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1001\/jamaoncol.2016.0639","volume":"2","author":"AG Sacher","year":"2016","unstructured":"Sacher, A. G. & Gandhi, L. Biomarkers for the clinical use of PD-1\/PD-L1 inhibitors in non-small-cell lung cancer: a review. JAMA Oncol. 2, 1217\u20131222 (2016).","journal-title":"JAMA Oncol."},{"key":"77375_CR3","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1001\/jamaoncol.2022.1981","volume":"8","author":"B Ricciuti","year":"2022","unstructured":"Ricciuti, B. et al. Association of high tumor mutation burden in non-small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 Blockade across PD-L1 expression levels. JAMA Oncol. 8, 1160\u20131168 (2022).","journal-title":"JAMA Oncol."},{"key":"77375_CR4","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/j.jtho.2020.05.019","volume":"15","author":"LM Sholl","year":"2020","unstructured":"Sholl, L. M. et al. The promises and challenges of tumor mutation burden as an immunotherapy biomarker: a perspective from the International Association for the Study of Lung Cancer Pathology Committee. J. Thorac. Oncol.: Publ. Int. Assoc. Study Lung Cancer 15, 1409\u20131424 (2020).","journal-title":"J. Thorac. Oncol.: Publ. Int. Assoc. Study Lung Cancer"},{"key":"77375_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009039","volume":"12","author":"MK Moutafi","year":"2024","unstructured":"Moutafi, M. K. et al. High-throughput transcriptome profiling indicates ribosomal RNAs to be associated with resistance to immunotherapy in non-small cell lung cancer (NSCLC). J. Immunother. Cancer 12, e009039 (2024).","journal-title":"J. Immunother. Cancer"},{"key":"77375_CR6","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41588-023-01355-5","volume":"55","author":"A Ravi","year":"2023","unstructured":"Ravi, A. et al. Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer. Nat. Genet. 55, 807\u2013819 (2023).","journal-title":"Nat. Genet."},{"key":"77375_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-55847-5","volume":"16","author":"N Captier","year":"2025","unstructured":"Captier, N. et al. Integration of clinical, pathological, radiological, and transcriptomic data improves prediction for first-line immunotherapy outcome in metastatic non-small cell lung cancer. Nat. Commun. 16, 614 (2025).","journal-title":"Nat. Commun."},{"key":"77375_CR8","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.lungcan.2020.12.027","volume":"152","author":"R Lobefaro","year":"2021","unstructured":"Lobefaro, R. et al. Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers. Lung Cancer 152, 165\u2013173 (2021).","journal-title":"Lung Cancer"},{"key":"77375_CR9","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1038\/s43018-024-00772-7","volume":"5","author":"T-G Chang","year":"2024","unstructured":"Chang, T.-G. et al. LORIS robustly predicts patient outcomes with immune checkpoint blockade therapy using common clinical, pathologic and genomic features. Nat. Cancer 5, 1158\u20131175 (2024).","journal-title":"Nat. Cancer"},{"key":"77375_CR10","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1093\/jnci\/djz094","volume":"111","author":"F Conforti","year":"2019","unstructured":"Conforti, F. et al. Sex-based heterogeneity in response to lung cancer immunotherapy: a systematic review and meta-analysis. J. Natl. Cancer Inst. 111, 772\u2013781 (2019).","journal-title":"J. Natl. Cancer Inst."},{"key":"77375_CR11","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41379-018-0029-3","volume":"31","author":"W-C Lee","year":"2018","unstructured":"Lee, W.-C. et al. Multiregion gene expression profiling reveals heterogeneity in molecular subtypes and immunotherapy response signatures in lung cancer. Mod. Pathol.: J. U. S. Can. Acad. Pathol., Inc. 31, 947\u2013955 (2018).","journal-title":"Mod. Pathol.: J. U. S. Can. Acad. Pathol., Inc."},{"key":"77375_CR12","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1038\/s43018-025-00979-2","volume":"8","author":"A Apavaloaei","year":"2025","unstructured":"Apavaloaei, A. et al. Tumor antigens preferentially derive from unmutated genomic sequences in melanoma and non-small cell lung cancer. Nat. Cancer 8, 1419\u20131437 (2025).","journal-title":"Nat. Cancer"},{"key":"77375_CR13","doi-asserted-by":"publisher","first-page":"e2037120","DOI":"10.1001\/jamanetworkopen.2020.37120","volume":"4","author":"K Sehgal","year":"2021","unstructured":"Sehgal, K. et al. Association of Performance Status With Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy. JAMA Netw. Open 4, e2037120 (2021).","journal-title":"JAMA Netw. Open"},{"key":"77375_CR14","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst, R. S. et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387, 1540\u20131550 (2016).","journal-title":"Lancet"},{"key":"77375_CR15","doi-asserted-by":"publisher","first-page":"S520","DOI":"10.1016\/j.jtho.2021.01.917","volume":"16","author":"T Hakozaki","year":"2021","unstructured":"Hakozaki, T., Kitadai, R., Kitagawa, S. & Hosomi, Y. P52.04 efficacy of immune checkpoint inhibitor monotherapy for patients with massive non-small-cell lung cancer. J. Thorac. Oncol. 16, S520\u2013S521 (2021).","journal-title":"J. Thorac. Oncol."},{"key":"77375_CR16","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.jtho.2022.10.014","volume":"18","author":"LG Paz-Ares","year":"2023","unstructured":"Paz-Ares, L. G. et al. First-Line Nivolumab Plus Ipilimumab with chemotherapy versus chemotherapy alone for metastatic NSCLC in CheckMate 9LA: 3-year clinical update and outcomes in patients with brain metastases or select somatic mutations. J. Thorac. Oncol. 18, 204\u2013222 (2023).","journal-title":"J. Thorac. Oncol."},{"key":"77375_CR17","doi-asserted-by":"publisher","first-page":"101374","DOI":"10.1016\/j.gendis.2024.101374","volume":"12","author":"Y Shen","year":"2025","unstructured":"Shen, Y., Chen, J.-Q. & Li, X.-P. Differences between lung adenocarcinoma and lung squamous cell carcinoma: Driver genes, therapeutic targets, and clinical efficacy. Genes Dis. 12, 101374 (2025).","journal-title":"Genes Dis."},{"key":"77375_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-023-00408-6","volume":"7","author":"T-G Chang","year":"2023","unstructured":"Chang, T.-G. et al. Optimizing cancer immunotherapy response prediction by tumor aneuploidy score and fraction of copy number alterations. NPJ Precis Oncol. 7, 54 (2023).","journal-title":"NPJ Precis Oncol."},{"key":"77375_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.843749","volume":"9","author":"H Feng","year":"2022","unstructured":"Feng, H. et al. Identification of Signature Genes and Characterizations of Tumor Immune Microenvironment and Tumor Purity in Lung Adenocarcinoma Based on Machine Learning. Front. Med. 9, 843749 (2022).","journal-title":"Front. Med."},{"key":"77375_CR20","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.lungcan.2017.07.024","volume":"111","author":"S Diem","year":"2017","unstructured":"Diem, S. et al. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer 111, 176\u2013181 (2017).","journal-title":"Lung Cancer"},{"key":"77375_CR21","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1200\/JCO.18.00149","volume":"37","author":"M Reck","year":"2019","unstructured":"Reck, M. et al. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. J. Clin. Oncol.:J. Am. Soc. Clin. Oncol. 37, 537\u2013546 (2019).","journal-title":"J. Clin. Oncol.:J. Am. Soc. Clin. Oncol."},{"key":"77375_CR22","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1158\/1078-0432.CCR-23-4027","volume":"30","author":"J van de Haar","year":"2024","unstructured":"van de Haar, J. et al. Combining Genomic Biomarkers to Guide Immunotherapy in Non-Small Cell Lung Cancer. Clin. Cancer Res. J. Am. Assoc. Cancer Res. 30, 1307\u20131318 (2024).","journal-title":"Clin. Cancer Res. J. Am. Assoc. Cancer Res."},{"key":"77375_CR23","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1097\/CM9.0000000000003824","volume":"138","author":"L Wang","year":"2025","unstructured":"Wang, L. et al. Role of artificial intelligence in medical image analysis. Chin. Med J. 138, 2879\u20132894 (2025).","journal-title":"Chin. Med J."},{"key":"77375_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.engmed.2025.100077","volume":"2","author":"S Joseph","year":"2025","unstructured":"Joseph, S. et al. GA-AGN: A generative adversarial network and attention gated network model for enhanced lung cancer detection using chest CT scans. EngMedicine 2, 100077 (2025).","journal-title":"EngMedicine"},{"key":"77375_CR25","first-page":"1322","volume":"37","author":"PC Austin","year":"2021","unstructured":"Austin, P. C., White, I. R., Lee, D. S. & van Buuren, S. Missing Data in Clinical Research: A Tutorial on Multiple Imputation. Can. J. Cardiol. 37, 1322\u20131331 (2021).","journal-title":"Can. J. Cardiol."},{"key":"77375_CR26","doi-asserted-by":"publisher","first-page":"e173","DOI":"10.1016\/S1470-2045(14)71116-7","volume":"16","author":"VP Balachandran","year":"2015","unstructured":"Balachandran, V. P., Gonen, M., Smith, J. J. & DeMatteo, R. P. Nomograms in oncology: more than meets the eye. Lancet Oncol. 16, e173\u2013e180 (2015).","journal-title":"Lancet Oncol."},{"key":"77375_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1249980","volume":"14","author":"S Liang","year":"2023","unstructured":"Liang, S. et al. The prognostic biological markers of immunotherapy for non-small cell lung cancer: current landscape and future perspective. Front. Immunol. 14, 1249980 (2023).","journal-title":"Front. Immunol."},{"key":"77375_CR28","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.lungcan.2020.12.027","volume":"152","author":"R Lobefaro","year":"2020","unstructured":"Lobefaro, R. et al. Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers. Lung Cancer 152, 165\u2013173 (2020).","journal-title":"Lung Cancer"},{"key":"77375_CR29","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.lungcan.2021.06.004","volume":"158","author":"B Tomasik","year":"2021","unstructured":"Tomasik, B., Bie\u0144kowski, M., Braun, M., Popat, S. & Dziadziuszko, R. Effectiveness and safety of immunotherapy in NSCLC patients with ECOG PS score \u22652 - Systematic review and meta-analysis. Lung Cancer 158, 97\u2013106 (2021).","journal-title":"Lung Cancer"},{"key":"77375_CR30","doi-asserted-by":"publisher","first-page":"849","DOI":"10.4103\/jcrt.jcrt_723_23","volume":"19","author":"J Gao","year":"2023","unstructured":"Gao, J., Zhang, C., Wei, Z. & Ye, X. Immunotherapy for early-stage non-small cell lung cancer: A system review. J. Cancer Res Ther. 19, 849\u2013865 (2023).","journal-title":"J. Cancer Res Ther."},{"key":"77375_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-85696-3","volume":"11","author":"CM Cramer-van der Welle","year":"2021","unstructured":"Cramer-van der Welle, C. M. et al. Real-world outcomes versus clinical trial results of immunotherapy in stage IV non-small cell lung cancer (NSCLC) in the Netherlands. Sci. Rep. 11, 6306 (2021).","journal-title":"Sci. Rep."},{"key":"77375_CR32","doi-asserted-by":"publisher","first-page":"e2214046","DOI":"10.1001\/jamanetworkopen.2022.14046","volume":"5","author":"S Popat","year":"2022","unstructured":"Popat, S. et al. Association Between Smoking History and Overall Survival in Patients Receiving Pembrolizumab for First-Line Treatment of Advanced Non-Small Cell Lung Cancer. JAMA Netw. Open 5, e2214046 (2022).","journal-title":"JAMA Netw. Open"},{"key":"77375_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2018-000406","volume":"3","author":"J Norum","year":"2018","unstructured":"Norum, J. & Nieder, C. Tobacco smoking and cessation and PD-L1 inhibitors in non-small cell lung cancer (NSCLC): a review of the literature. ESMO Open 3, e000406 (2018).","journal-title":"ESMO Open"},{"key":"77375_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.703143","volume":"11","author":"W Zhao","year":"2021","unstructured":"Zhao, W. et al. Impact of smoking history on response to immunotherapy in non-small-cell lung cancer: a systematic review and meta-analysis. Front. Oncol. 11, 703143 (2021).","journal-title":"Front. Oncol."},{"key":"77375_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1422160","volume":"14","author":"D Luo","year":"2024","unstructured":"Luo, D. et al. Effect of smoking status on immunotherapy for lung cancer: a systematic review and meta-analysis. Front. Oncol. 14, 1422160 (2024).","journal-title":"Front. Oncol."},{"key":"77375_CR36","doi-asserted-by":"publisher","first-page":"413","DOI":"10.21037\/tlcr.2019.08.09","volume":"8","author":"Y Xu","year":"2019","unstructured":"Xu, Y. et al. The association of PD-L1 expression with the efficacy of anti-PD-1\/PD-L1 immunotherapy and survival of non-small cell lung cancer patients: a meta-analysis of randomized controlled trials. Transl. Lung Cancer Res. 8, 413\u2013428 (2019).","journal-title":"Transl. Lung Cancer Res."},{"key":"77375_CR37","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.3389\/fonc.2020.01671","volume":"10","author":"X Yan","year":"2020","unstructured":"Yan, X., Tian, X., Wu, Z. & Han, W. Impact of age on the efficacy of immune checkpoint inhibitor-based combination therapy for non-small-cell lung cancer: a systematic review and meta-analysis. Front. Oncol. 10, 1671 (2020).","journal-title":"Front. Oncol."},{"key":"77375_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02580-1","volume":"20","author":"Y Wang","year":"2022","unstructured":"Wang, Y. et al. Comparison between immunotherapy efficacy in early non-small cell lung cancer and advanced non-small cell lung cancer: a systematic review. BMC Med. 20, 426 (2022).","journal-title":"BMC Med."},{"key":"77375_CR39","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1093\/annonc\/mds289","volume":"24","author":"F Petrelli","year":"2012","unstructured":"Petrelli, F. & Barni, S. Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer. Ann. Oncol.: J. Eur. Soc. Med. Oncol. 24, 186\u2013192 (2012).","journal-title":"Ann. Oncol.: J. Eur. Soc. Med. Oncol."},{"key":"77375_CR40","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1016\/j.jtho.2019.05.030","volume":"14","author":"J Rutkowski","year":"2019","unstructured":"Rutkowski, J., Saad, E. D., Burzykowski, T., Buyse, M. & Jassem, J. Chronological trends in progression-free, overall, and post-progression survival in first-line therapy for advanced NSCLC. J. Thorac. Oncol.: Off. Publ. Int. Assoc. Study Lung Cancer 14, 1619\u20131627 (2019).","journal-title":"J. Thorac. Oncol.: Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"77375_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0647-4","volume":"7","author":"L Fancello","year":"2019","unstructured":"Fancello, L., Gandini, S., Pelicci, P. G. & Mazzarella, L. Tumor mutational burden quantification from targeted gene panels: major advancements and challenges. J. Immunother. Cancer 7, 183 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"77375_CR42","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1016\/j.annonc.2021.09.016","volume":"32","author":"DM Vega","year":"2021","unstructured":"Vega, D. M. et al. Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project. Ann. Oncol.: J. Eur. Soc. Med. Oncol. 32, 1626\u20131636 (2021).","journal-title":"Ann. Oncol.: J. Eur. Soc. Med. Oncol."},{"key":"77375_CR43","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.ccell.2025.03.029","volume":"43","author":"G Arango-Argoty","year":"2025","unstructured":"Arango-Argoty, G. et al. AI-driven predictive biomarker discovery with contrastive learning to improve clinical trial outcomes. Cancer Cell 43, 875\u2013890.e8 (2025).","journal-title":"Cancer Cell"},{"key":"77375_CR44","doi-asserted-by":"publisher","first-page":"135","DOI":"10.21037\/tlcr-21-815","volume":"11","author":"Y Uehara","year":"2022","unstructured":"Uehara, Y. et al. Association between the baseline tumor size and outcomes of patients with non-small cell lung cancer treated with first-line immune checkpoint inhibitor monotherapy or in combination with chemotherapy. Transl. Lung Cancer Res. 11, 135\u2013149 (2022).","journal-title":"Transl. Lung Cancer Res."},{"key":"77375_CR45","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s43018-019-0008-8","volume":"1","author":"V Anagnostou","year":"2020","unstructured":"Anagnostou, V. et al. Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer. Nat. Cancer 1, 99\u2013111 (2020).","journal-title":"Nat. Cancer"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77375-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77375-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77375-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:02:10Z","timestamp":1790766130000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77375-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["77375"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-77375-6","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"assertion":[{"value":"9 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"10348"}}